comparemela.com

Latest Breaking News On - Jorge mercado friday - Page 2 : comparemela.com

UC Santa Barbara, Goleta reach settlement agreement on student housing

Goleta and the UC Regents have reached a settlement on the 2021 lawsuit in which the city alleged UC Santa Barbara was not building student and faculty housing as provided for in the university's 2010 long range development plan. Announced March 22, the city alleged that the lack of long range housing plans negatively impacted

Updated: Thousand Oaks biotech firm emerges from stealth with $135M in funding

Editor's note: This story was updated on Feb. 23 to include more info about the company's lead treatment. Latigo Biotherapeutics, a Thousand Oaks-based biotech firm that was originally founded by Westlake Village BioPartners, emerged from stealth mode on Feb. 14, announcing $135 million in Series A financing. Latigo is a clinical-stage biotechnology company looking to

Santa Barbara lottery app sold for $750M | Pacific Coast Business Times

Jackpocket opened its Santa Barbara headquarters in 2021. (courtesy photo) Santa Barbara-based Jackpocket, a lottery courier software company, has reached an agreement to be purchased by DraftKings, one of the largest digital sports entertainment apps in the country, for approximately $750 million. Announced Feb. 15, 55% of the deal will be paid in cash with

Deckers announces positive earnings, CEO succession plans | Pacific Coast Business Times

Goleta-based Deckers saw shares jump up 14% on Feb. 2, one day after the company delivered record results during its third-quarter earnings release as well as the news that longtime President and CEO Dave Powers will be retiring on Aug. 1. According to a press release, Powers will still be serving on Deckers' board of

Arcutis treatment gets additional FDA approval | Pacific Coast Business Times

Westlake Village-based Arcutis Biotherapeutics announced that its main treatment option, Zoryve, received approval from the U.S. Drug and Food Administration for treating a skin condition called seborrheic dermatitis, the company announced on Dec. 15 It is the second FDA approval received by Arcutis’ Zoryve, being approved to be used in individuals nine years of age

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.